NCT07365566

Brief Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
3mo left

Started Feb 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress46%
Feb 2026Aug 2026

First Submitted

Initial submission to the registry

January 16, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 26, 2026

Completed
29 days until next milestone

Study Start

First participant enrolled

February 24, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

5 months

First QC Date

January 16, 2026

Last Update Submit

April 27, 2026

Conditions

Keywords

parkinsonREM sleeppainREM sleep behavior disordernarcolepsy Type 1sleep

Outcome Measures

Primary Outcomes (1)

  • Comparison of the intensity of chronic pain between patients with iRBD and a control group of patients

    Measuring the Visual Analog Scale (VAS) between patients with iRBD without diagnosis of PD and a control group of patients diagnosed with narcolepsy type 1 who present RBD (Rapid eye movement sleep behavior disorder).

    2 hours after the inclusion

Secondary Outcomes (5)

  • Describe semiological characteristics of pain in RBD patients

    2 hours after the inclusion

  • Compare the presence of chronic pain

    2 hours after the inclusion

  • Assessing Pain Characteristics

    2 hours after the inclusion

  • Assessment of thermal pain threshold and tolerance

    2 hours after the inclusion

  • Assessment of correlations between the intensity of chronic pain

    2 hours after the inclusion

Study Arms (2)

Idiopathic REM sleep Behavior disorder (iRBD) Group

EXPERIMENTAL

Patients who have an idiopathic REM sleep Behavior Disorder

Other: Thermo test painOther: Pain questionnairesOther: No motors symptoms evaluations

Idiopathic REM Sleep Bhavior Disorder (iRBD) + narcolepsy type 1

ACTIVE COMPARATOR

patients who have an iRBD and who have type 1 narcolepsy

Other: Thermo test painOther: Pain questionnairesOther: No motors symptoms evaluations

Interventions

Patients will undergo a pain test, also called a thermotest, which consists of determining pain thresholds using a thermometer applied to the hand.

Idiopathic REM Sleep Bhavior Disorder (iRBD) + narcolepsy type 1Idiopathic REM sleep Behavior disorder (iRBD) Group

Patients will complete various questionnaires about pain

Idiopathic REM Sleep Bhavior Disorder (iRBD) + narcolepsy type 1Idiopathic REM sleep Behavior disorder (iRBD) Group

Patients will complete questionnaires

Idiopathic REM Sleep Bhavior Disorder (iRBD) + narcolepsy type 1Idiopathic REM sleep Behavior disorder (iRBD) Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with iRBD confirmed by polysomnography;
  • No clinical diagnosis of Parkinson's disease or other diagnosis of neurodegenerative disease;
  • Ability to understand and complete study procedures and questionnaires;
  • Control group:
  • Diagnosed with narcolepsy type 1;
  • Coexisting REM sleep behavior disorder confirmed by polysomnography;
  • Ability to understand and complete study procedures and questionnaires;

You may not qualify if:

  • Diagnosed Parkinson's Disease, dementia with Lewy bodies or multiple system atrophy;
  • Severe depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM V);
  • Inability to complete study procedures or questionnaires.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Expert Parkinson Hôpital Pierre Paul Riquet Place du Docteur Baylac

Toulouse, 31059, France

RECRUITING

MeSH Terms

Conditions

REM Sleep Behavior DisorderPain

Condition Hierarchy (Ancestors)

REM Sleep ParasomniasParasomniasSleep Wake DisordersNervous System DiseasesMental DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 16, 2026

First Posted

January 26, 2026

Study Start

February 24, 2026

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations